Janssen says it is “considering all options including an appeal” after NICE today said that its nasal spray, Spravato(esketamine), should not be made available on the National Health Service in England for patients with treatment-resistant major depressive disorder (TRD).
The rejection by the health technology assessment institute was published on 27 May in a final appraisal document (FAD) for...







